Drotrecogin alpha (activated). Market analysis

Nature Reviews Drug Discovery

Volumn 2, Issue 1, 2003, Pages 13-14

  Lebbos, John ^a   Bradsher, Julia ^a   Kirkpatrick, Peter ^b  

^a Decision Resources Inc   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ACTIVATED PROTEIN C; ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; CD14 ANTIGEN; CYTOKINE RECEPTOR; DROTRECOGIN; E 5531; ENDOTOXIN ANTIBODY; GR 270773; IC 14; IMMUNOMODULATING AGENT; INTERLEUKIN 6; PHOSPHOLIPASE A2; PLACEBO; PROTEIN C; RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; VARESPLADIB; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN KINASE C; RECOMBINANT PROTEIN;

BLEEDING; CAUSE OF DEATH; CLINICAL TRIAL; DRUG ACTIVITY; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG MARKETING; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG UTILIZATION; HUMAN; INCIDENCE; NOTE; PRIORITY JOURNAL; REIMBURSEMENT; SEPSIS; ARTICLE; ENZYME ACTIVATION; HEALTH CARE COST; MORTALITY; PATHOLOGY;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CLINICAL TRIALS; DRUG UTILIZATION; ENZYME ACTIVATION; HEALTH CARE SECTOR; HUMANS; PROTEIN C; PROTEIN KINASE C; RECOMBINANT PROTEINS; SEPSIS;

EID: 0037270357     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd991     Document Type: Note

References (6)

1. Bone, R. C., Grodzin, R. J. & Balk, R. A. Sepsis: a new hypothesis for the pathogenesis of the disease process. Chest 112, 235-243 (1997).
2. Bernard, G. R. et al. Efficacy and safety of activated protein C for the treatment of severe sepsis. N. Engl. J. Med. 344, 699-709 (2001).
3. Knaus, W. A. et al. APACHE II: a severity of disease classification system. Crit. Care Med. 13, 818-829 (1985).
4. FDA Product Approval Information [online] (cited 1 Dec 2002) http://www.fda.gov/cber/label/droteli112101LB.pdf
5. Angus, D. et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit. Care Med. 29, 1303-1310 (2001).
6. Angus, D. et al. The effects of drotrecogin alfa (activated) on long-term survival after severe sepsis. American College of Chest Physicians Annual Meeting Abstract S144 (2002).